Actively Recruiting
The PARTUM Trial Comparing Low-Dose Aspirin and Heparin to Prevent Blood Clots After Delivery in Women at Risk
Led by University of Calgary · Updated on 2026-07-27
8805
Participants Needed
12
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating if taking low-dose aspirin daily for 6 weeks after delivery is as effective as the usual care of low-molecular-weight heparin injections in preventing venous thromboembolism VTE, which includes blood clots in the legs or lungs, in postpartum individuals with risk factors for VTE. This is a Phase 3, randomized, open-label trial designed to compare these two prevention strategies to reduce undue morbidity after childbirth. Participants will be randomly assigned to receive either low-dose aspirin 75-100 mg daily for 42 days after delivery or the usual care low-molecular-weight heparin regimen as prescribed by their healthcare provider. The aspirin dose depends on country availability, and the heparin dosage and duration are determined individually. Follow-up assessments will occur at 6 weeks and 90 days after randomization to monitor outcomes. During the study, participants will be monitored for symptomatic VTE and other related outcomes such as bleeding events, wound complications, and arterial thromboembolism. Researchers will assess these outcomes at 6 weeks and 90 days after starting the assigned treatment. The study aims to track safety, adherence, and effectiveness over this period, with total participation lasting about three months post-delivery.
CONDITIONS
Brief Title
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Research Team
L
Leslie Skeith, MD
J
Jill Baxter, BSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here